COMMUNIQUÉS West-GlobeNewswire

Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
30/03/2026
MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced the closing of the sale of Cyprium’ [...]
ProHealth Longevity BPC‑157 Claims Evaluated: Most Effective BPC157 Peptide Brand on the Market (2026)
30/03/2026
A 2026 consumer information guide examining ProHealth BPC-157 oral peptide capsule details, arginate vs acetate formulation context, preclinical tissue repair research, regulatory status, third-party testing [...]
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
30/03/2026
RenovoCath ® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated in 2027 With $13 [...]
Range Impact Reports Full Year 2025 Financial Results
31/03/2026
CLEVELAND, OHIO, March 30, 2026 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact” or the “Company”), a public company dedicated to acquiring, reclaiming and repurposing distressed coal mine properties [...]
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
30/03/2026
– Announced positive initial comparative analytical results, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX ® – – Reported positive FDA BPD Type 2a meeting, with FDA [...]
Alvotech Files Annual Report with the SEC
31/03/2026
REYKJAVIK, Iceland, March 30, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the U.S. Securities and Exchange Commission ( [...]
Vicarious Surgical Completes Integrated Benchtop Testing of Full Surgical Instrument Suite for Ventral Hernia Repair
30/03/2026
WALTHAM, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the “Company”), today announced [...]
Invivyd Announces Presentation at the World Vaccine Congress Washington
30/03/2026
Chief Scientific Officer, Robert Allen, Ph.D., presented as part of the “Antibodies for Infectious Disease Workshop” at the World Vaccine Congress Washington Presentation titled “Developing mAb Therapies that Keep Pace [...]
MemoryON Claims Evaluated: Hidden Details Emerge About Memory On Brain Support Supplementation for Memory Loss
31/03/2026
A 2026 informational consumer report on MemoryON's cognitive health formula, Bacopa Monnieri and Phosphatidylserine dosage research, St. John's Wort safety considerations, nootropic ingredient analysis, pricing [...]
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
30/03/2026
SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on track for 1H 2026 First CMC Development and Readiness Program (CDRP) meeting [...]
BIO GREEN MED SOLUTION REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
30/03/2026
KUALA LUMPUR, MALAYSIA, March 30, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. ("BGMS," the "Company" or “we,” formerly Cyclacel Pharmaceuticals, Inc.) (NASDAQ: BGMS), a diversified company engaged primarily in [...]
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
30/03/2026
REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy [...]
Alvotech files Annual Report with the SEC
31/03/2026
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the U.S. Securities and Exchange Commission (SEC), [...]
Vireo Growth Inc. Announces Effectiveness of Management Services Agreement with PharmaCann Inc.
30/03/2026
Management Services Agreement went into effect on March 22, 2026, allowing Vireo to manage certain PharmaCann Colorado assets through closing, which is expected in Q2’26 MINNEAPOLIS, March 30, 2026 (GLOBE NEWSWIRE) -- [...]
Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease
30/03/2026
PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat population Phase 1b data demonstrate endoscopic improvement, with a 47.5% [...]
Inventiva reports 2025 full year results and provides a business update
30/03/2026
Revenues of €4.5 million for the full year of 2025 Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits 1 as at December 31, 2025 Completed a U.S. registered public offering for gross [...]
Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission
30/03/2026
Company advances manufacturing, toxicology, patent and regulatory milestones while building a broader pharmaceutical development platform Jericho, New York, March 30, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, [...]
INmune Bio Inc. Announces 2025 Results and Provides Business Update
30/03/2026
Company to Host Conference Call Today, March 30, at 4:30pm ET BOCA RATON, Fla., March 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on [...]
Inventiva publie ses résultats financiers annuels 2025 et fait le point sur son activité
30/03/2026
Chiffre d'affaires de 4,5 millions d'euros pour l’année 2025 Trésorerie et équivalents de trésorerie à 99,3 millions d’euros et 131,6 millions d'euros en dépôts à court terme 1 au 31 décembre 2025 Réalisation d'une [...]

Pages